We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01308372
First Posted: March 4, 2011
Last Update Posted: November 7, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The purpose of this study is to evaluate the proportion of patients which present a high cardiovascular risk estimated by the SCORE scale, in general practice consultations of the 7 French regions (Paris area, North-East, Paris basin, West, South-West, South- East, Mediterranean area)

Condition
Healthy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Cardiovascular Risk in General Practice in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluation of cardiovascular risk in general practice in France estimated by the SCORE scale [ Time Frame: 1 week ]

Secondary Outcome Measures:
  • Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 2008 scale D'Agostino [ Time Frame: 1 week ]
  • Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 1998 scale Wilson [ Time Frame: 1 week ]
  • Evaluation of arteries age evaluation by SCORE [ Time Frame: 1 week ]

Enrollment: 9246
Study Start Date: October 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;

Detailed Description:
MC MD
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Primary care
Criteria

Inclusion Criteria:

  • Without any personal history of coronary disease
  • Non treated with lipid-lowering agents
  • Lipid test = 1 year old
  • Presenting at least one cardiovascular risk
  • Visiting their General Practitioner

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01308372


  Show 587 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Eric BRUCKERT, Pr. Hôpital Pitié-Salpétrière - Service Endocrinologie-Métabolisme
Principal Investigator: Jean DALLONGEVILLE, Dr. Institut Pasteur de Lille - Unité d'Epidémiologie et de santé publique Inserm UMR 744
Principal Investigator: Jean FERRIERES, Pr. CHU Rangueil - Service de Cardiologie B - Toulouse
Principal Investigator: Serge KOWNATOR, Dr. Thionville -Société Française de Cardiologie
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01308372     History of Changes
Other Study ID Numbers: NIS-CFR-XXX-2011/1
First Submitted: February 18, 2011
First Posted: March 4, 2011
Last Update Posted: November 7, 2011
Last Verified: November 2011

Keywords provided by AstraZeneca:
cardiovascular risk
France
General practice
Primary prevention
Non treated patients